Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
124 hedge funds and large institutions have $900M invested in Ra Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 4 closing their positions.
750% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 4
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
41% more capital invested
Capital invested by funds: $636M → $900M (+$264M)
32% more funds holding
Funds holding: 94 → 124 (+30)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$15.1M |
| 2 |
BlackRock
New York
|
+$11.3M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.94M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$6.77M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$6.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMPI
Morgenthaler Management Partners IX
Portola Valley,
California
|
-$27.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$16.1M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$8.19M |
| 4 |
Man Group
London,
United Kingdom
|
-$2.94M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.45M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$195K | -10,736 | Closed |
|
|
TRCT
127
Tower Research Capital (TRC)
New York
| – | -$44K | -2,397 | Closed |
|
|
AG
128
Advisor Group
Phoenix,
Arizona
| – | +$279 | +13 | New |
|
RARX Hedge Fund Activity: Q1 2019 in Review
124 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q1 2019, worth a combined $900M — up 41% from $636M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new RARX positions and 4 closed out — a net gain of 30 holders — while 44 added to existing stakes and 30 trimmed.
The largest buyer was State Street, adding an estimated $15.1M. The largest seller was Morgenthaler Management Partners IX, cutting an estimated $27.3M.
- 124 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q1 2019, up from 94 in Q4 2018.
- Funds reported $900M of Ra Pharmaceuticals, Inc. Common Stock stock for Q1 2019, up 41% quarter-over-quarter.
- 34 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of +30 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was State Street, an estimated $15.1M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Morgenthaler Management Partners IX, an estimated $27.3M sold.
Based on aggregated 13F filings for Q1 2019.